EGFR and non-small cell lung carcinoma: The frequency of Oligo-PD in EGFR-mutated NSCLC after treatment with first- and second-generation EGFR-TKIs has previously been shown to be 15–45%, while the frequency of Oligo-PD after osimertinib has been reported to be 73–75%.